CG OncologyvsJohnson & Johnson

CGON and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

CGON

CG Oncology, Inc.

$79.47

Value $7.1B

-2.97%
CGON's page

CG Oncology (CGON) has a market value of $7.1B and Johnson & Johnson (JNJ) $652B. Over the last year, with dividends, CGON moved +86.5% and JNJ +36.6%. Dividend yield: CGON none, JNJ 1.95%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CGON$7.1B

    JNJ$652B

    JNJ is 92 times CGON

  • Revenue, 12 months

    CGON$6.2M

    JNJ$99.3B

    JNJ is 16,110 times CGON

  • Net income, 12 months

    CGON-$237M

    JNJ$16.1B

  • Operating margin

    CGON-4,293.5%

    JNJ–

  • ROIC

    CGON-22.9%

    JNJ12.4%

    35.3 points apart

  • P/E

    CGON–

    JNJ40.5

  • Dividend yield

    CGON0.0%

    JNJ2.0%

    2.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CGON+86.5%

JNJ+36.6%

100150200DecFebAprJunAugOct
Returns by period
PeriodCGONWith dividendsJNJWith dividends
1 year since November 19, 2025+86.5%Price +86.5%+36.6%Price +33.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CGONCG OncologyJNJJohnson & Johnson

Valuation

CGONJNJ
Valuation
Price$79.47$270.47
Market value$7.1B$652B
Enterprise value (EV)$6.1B$679B
P/E–40.5
P/E, 5-year median–21.9
P/B7.28.0
EV/EBIT–38.3
Free cash flow yield–3.2%

Results and growth

CGONJNJ
Results and growth
Revenue, 12 months$6.2M$99.3B
Net income, 12 months-$237M$16.1B
Free cash flow, 12 months-$189M$20.6B
Earnings per share, 12 months-$2.76$6.59
Revenue growth, year on year254.7%6.1%
Revenue growth a year, past+345.0%over 2 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

CGONJNJ
Margins and returns on capital
Gross margin–67.6%
Operating margin-4,293.5%–
Net margin-3,851.1%16.2%
ROIC-22.9%12.4%
ROE-26.1%19.7%

Balance sheet

CGONJNJ
Balance sheet
Cash$984M$17.2B
Total debt$9.2M$44.7B
Net debt / EBITDA–1.1
Interest cover–18.0×

Dividends and buybacks

CGONJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CGON or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, CG Oncology or Johnson & Johnson?

By market value, Johnson & Johnson ($652B) is about 91.8 times CG Oncology ($7.1B), at today's prices.

How did CGON and JNJ stock do over the last 1 years?

Since November 19, 2025, CGON's price moved +86.5% and JNJ's +33.6%. With dividends: CGON +86.5% (+86.5% a year), JNJ +36.6% (+36.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, CGON or JNJ?

The dividend yield at today's price is none for CG Oncology and 1.95% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, CG Oncology or Johnson & Johnson?

Over the last twelve months, the net margin was -3,851.1% for CG Oncology and 16.2% for Johnson & Johnson, and the operating margin -4,293.5% and –. Revenue was $6.2M and $99.3B.

Which is the better investment, CG Oncology or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.